Testing sensitivity to cd30 targeting via brentuximab vedotin in multiple myeloma
Introduction Multiple myeloma (MM) is a hematological malignancy characterized by terminally differentiated plasma cells (PCs), immunosuppression and end-organ damage. Despite the therapeutic progress achieved with the introduction of the proteasome inhibitors, immunomodulators and monoclonal antib...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2020-09-01
|
| Series: | Hematology Reports |
| Online Access: | https://www.pagepress.org/journals/index.php/hr/article/view/8921 |